A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

Cystic fibrosis (CF) is a genetic disorder that primarily affects the lungs and digestive system, leading to severe respiratory and nutritional challenges. Recent research has focused on ...

Lupin receives USFDA approval for its generic version of Ivacaftor oral granules, a treatment for cystic fibrosis. The approval marks a significant step for Lupin in the US market.

Cystic fibrosis is a rare ... a deuterated analogue of Vertex’s first-in-class potentiator ivacaftor. Deutivacaftor, previously called VX-561 and before that CTP-656, carries nine heavy ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

Ivacaftor oral granules, 25 mg, 50 mg and 75 mg per unit dose packet are indicated for the treatment of cystic fibrosis (CF) in patients aged four months and older who have at least one mutation ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis ... who have CF with ivacaftor.